DLPC is an unusual phospholipid and a trace component of the dietary supplement lecithin.
Dr. David D. Moore, professor of molecular and cellular biology at BCM, and his colleagues at first thought that DLPC would provide a useful tool in studying the function of a receptor protein – liver receptor homolog -1 or LRH-1 – that regulates the production of bile acids in the liver.
Stimulating LRH-1 activity
Studies in mice soon showed that DLPC could stimulate LRH-1 activity. In addition to a small increase in bile acid levels, DLPC improved regulation of glucose and fat within the liver. A report on this work appears in the current issue of the journal Nature. Moore is collaborating with Dr. Lawrence Chan, director of the Diabetes and Endocrine Research Center at BCM, on a pilot study to find out how well DLPC works in patients with prediabetes.
“We know it works well in mice,” said Moore. The link of LRH-1 to bile acids may contribute to its effect on glucose levels and fat because small, non-toxic increases in bile acid levels can improve metabolic disorders.
Dr. Jae Man Lee, then a graduate student in Moore’s laboratory, first proposed screening compounds to see which activated LRH-1. He found that DLPC, a structurally unusual phosphatidylcholine (a form of phospholipid that is important in the formation of cell membranes) enhanced LRH-1 activity in cells.
In mice, DLPC induced the production of bile acid enzymes and lowered fat in the liver. It also increased levels of bile acids and regulated glucose or sugar circulating in the blood. In two kinds of mice that had resistance to insulin, DLPC also decreased fatty liver and lowered glucose levels in the blood. However, DLPC had no effect in mice that had no LRH-1 in the liver.
The effect on the insulin resistant mice was striking.
“Their overall body weight was not changed,” said Moore. “But they had improved sensitivity to insulin (which helps keep glucose levels in check) and less fatty livers. We are interested in why it gets rid of the fat in the liver.”
DLPC decreased the levels of proteins associated with formation of fatty acids and triglycerides, including a key regulator called SREBP-1c that encourages the deposition of fat in tissues.
“DLPC is a natural product,” said Moore. “Lecithin is a mixture of many compounds but DLPC is one of them.”
Clinical study underway
The ongoing clinical study, which involves people who are overweight but not diabetic, employs an approved form of DLPC that is used in liposomes, little globules of fat that take drugs into the body. An initial glucose tolerance test to determine how sensitive the people are to insulin at the start of the study is followed by another after the subjects take DLPC or a placebo for two months. Neither the patients in study nor the physicians know who is getting DLPC and who is getting the placebo.
The study is still enrolling subjects, and there are no results yet. Those who wish to enroll can call Dr. Kerem Ozer at 713-798-7684.
Others who took part in the basic science research include Dr. Yoon Kwang Lee and Jennifer L. Mamrosh of BCM, Dr. Scott A. Busby and Dr. Patrick R. Griffin of Scripps Research Institute in Jupiter, Florida and Dr. Manish C. Pathak and Dr. Eric A. Ortlund of Emory University School of Medicine in Atlanta. (Yoon Kwang Lee is now at Northeastern Ohio Colleges of Medicine and Pharmacy in Rootstown, Ohio).
Funding for this work came from the National Institutes of Health, the Alkek Foundation, the National Institute of Diabetes and Digestive and Kidney Diseases and the Robert R.P. Doherty Jr. – Welch Chair in Science.
# # #
Dr. Moore holds the Robert R.P. Doherty Jr. – Welch Chair in Science.